Eli Lilly (LLY) Receivables (2009 - 2026)
Eli Lilly posted quarterly Receivables of $21.2 billion for Q1 2026, up 51.23% year-on-year from $14.0 billion in Q1 2025, and up 5.07% on a QoQ basis from $20.2 billion in Q4 2025.
Eli Lilly (LLY) has 18 years of Receivables data on file, last reported at $21.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 51.23% year-over-year to $21.2 billion; the trailing twelve-month figure through Mar 2026 stood at $21.2 billion (up 51.23% YoY), and the FY2025 full-year result was $20.2 billion, up 51.82% from the prior year.
- Receivables for Q1 2026 stood at $21.2 billion, up from $20.2 billion in the prior quarter.
- Across five years, Receivables topped out at $21.2 billion in Q1 2026 and bottomed at $7.7 billion in Q2 2022.
- The 5-year median for Receivables is $11.3 billion (2023), against an average of $12.5 billion.
- The widest annual swing landed in 2022, when Receivables rose 5.31%; it then soared 61.45% in 2025.
- A 5-year view of Receivables shows it stood at $8.6 billion in 2022, then soared by 32.45% to $11.3 billion in 2023, then grew by 17.11% to $13.3 billion in 2024, then jumped by 51.82% to $20.2 billion in 2025, then increased by 5.07% to $21.2 billion in 2026.
- The last three Receivables figures came in at $21.2 billion (Q1 2026), $20.2 billion (Q4 2025), and $19.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 11.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.18 Bn |
| Dec 31, 2025 | 20.16 Bn |
| Sep 30, 2025 | 19.46 Bn |
| Jun 30, 2025 | 17.21 Bn |
| Mar 31, 2025 | 14.00 Bn |
| Dec 31, 2024 | 13.28 Bn |
| Sep 30, 2024 | 12.05 Bn |
| Jun 30, 2024 | 13.08 Bn |
| Mar 31, 2024 | 10.01 Bn |
| Dec 31, 2023 | 11.34 Bn |
| Sep 30, 2023 | 10.36 Bn |
| Jun 30, 2023 | 9.17 Bn |
| Mar 31, 2023 | 9.02 Bn |
| Dec 31, 2022 | 8.56 Bn |
| Sep 30, 2022 | 8.32 Bn |
| Jun 30, 2022 | 7.67 Bn |
| Mar 31, 2022 | 7.81 Bn |
| Dec 31, 2021 | 8.13 Bn |
| Sep 30, 2021 | 7.03 Bn |
| Jun 30, 2021 | 6.90 Bn |
| Mar 31, 2021 | 6.66 Bn |
| Dec 31, 2020 | 6.93 Bn |
| Sep 30, 2020 | 5.84 Bn |
| Jun 30, 2020 | 5.78 Bn |
| Mar 31, 2020 | 6.35 Bn |
| Dec 31, 2019 | 5.54 Bn |
| Sep 30, 2019 | 5.54 Bn |
| Jun 30, 2019 | 5.59 Bn |
| Mar 31, 2019 | 5.18 Bn |
| Dec 31, 2018 | 5.78 Bn |
| Sep 30, 2018 | 5.65 Bn |
| Jun 30, 2018 | 5.58 Bn |
| Mar 31, 2018 | 5.27 Bn |
| Dec 31, 2017 | 5.26 Bn |
| Sep 30, 2017 | 5.01 Bn |
| Jun 30, 2017 | 4.96 Bn |
| Mar 31, 2017 | 4.61 Bn |
| Dec 31, 2016 | 4.77 Bn |
| Sep 30, 2016 | 4.52 Bn |
| Jun 30, 2016 | 4.49 Bn |
| Mar 31, 2016 | 4.19 Bn |
| Dec 31, 2015 | 1.12 Bn |
| Sep 30, 2015 | 4.07 Bn |
| Jun 30, 2015 | 4.10 Bn |
| Mar 31, 2015 | 3.83 Bn |
| Dec 31, 2014 | 3.80 Bn |
| Sep 30, 2014 | 3.63 Bn |
| Jun 30, 2014 | 3.75 Bn |
| Mar 31, 2014 | 3.75 Bn |
| Dec 31, 2013 | 4.02 Bn |
| Sep 30, 2013 | 4.00 Bn |
| Jun 30, 2013 | 4.21 Bn |
| Mar 31, 2013 | 4.03 Bn |
| Dec 31, 2012 | 3.89 Bn |
| Sep 30, 2012 | 527.30 Mn |
| Jun 30, 2012 | 3.18 Bn |
| Mar 31, 2012 | 529.20 Mn |
| Dec 31, 2011 | 640.20 Mn |
| Sep 30, 2011 | 564.40 Mn |
| Jun 30, 2011 | 3.83 Bn |
| Mar 31, 2011 | 488.80 Mn |
| Dec 31, 2010 | 3.49 Bn |
| Sep 30, 2010 | 3.34 Bn |
| Jun 30, 2010 | 3.07 Bn |
| Mar 31, 2010 | 3.19 Bn |
| Dec 31, 2009 | 3.34 Bn |
| Sep 30, 2009 | 3.02 Bn |
| Jun 30, 2009 | 2.84 Bn |